XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.98

-0.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	8/28/2007 2:00:55 PM
	of 17367

Alliance with Pfizer 10:55 XOMA XOMA Limited: Alliance with Pfizer provides clear validation of antibody research - Rodman and Renshaw (2.76 +0.48) -Update- Rodman and Renshaw notes that XOMA announced that it has licensed to Pfizer (PFE) the non-exclusive, worldwide rights to its bacterial cell expression technology for phage display and other research, development and manufacturing of antibody products. Firm believes the alliance provides clear validation of XOMA's antibody research technology. Firm also says the recent huge increase in short interest should provide upward support to the stock as the short interest gets covered. They believe today's announcement should help XOMA reach its previously stated goal of profitability by '09. The PFE deal represents a significant source of upside to firms' present valuation, as they have not yet factored any revs from the B.C.E. platform.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next